Denali Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.5%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
-$2.29next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
AVLAYAH Commercial Launch Progress QuarterlyTarget: Establishment of broad payer coverage and treatment of initial commercial patient cohorts in the U.S.
Cash and Marketable Securities Balance Quarterly1.1BTarget: Maintain sufficient liquidity to fund operations into at least 2028
DNL126 (ETV:SGSH) Phase 1/2 Study Completion AnnuallyTarget: Complete Phase 1/2 study in 2026 to support a planned regulatory submission for accelerated approval in 2027
Watch Items
- DNL593 (PTV:PGRN) Phase 1/2 Clinical Data ReadoutTrigger: Initial clinical data expected by the end of 2026Action: Evaluate proximal and distal biomarkers in FTD-GRN patients following Takeda's co-development termination
- DNL151 (BIIB122) Phase 2a BEACON Study ProgressTrigger: Clinical data readout expected in the first half of 2027Action: Monitor safety, pharmacokinetics, and lysosomal pathway engagement in LRRK2 pathogenic variant carriers following the discontinuation of the idiopathic Parkinson's program
Research as of 20 Jun 2026